Paradigm Biopharmaceuticals company info

What does Paradigm Biopharmaceuticals do?
Paradigm Biopharmaceuticals (ASX:PAR) is an Australian biotechnology company developing injectable pentosan polysulfate sodium (iPPS) for the treatment of osteoarthritis (OA). OA is a degenerative joint disease that affects millions of people worldwide, and there is currently no cure. Paradigm's operations are focused on the development and commercialisation of iPPS. The company is currently conducting Phase 3 clinical trials of iPPS for the treatment of knee OA, and it expects to submit regulatory applications for approval in 2024. Paradigm is also exploring the use of iPPS to treat other forms of OA, such as hip and shoulder OA.
Paradigm Biopharmaceuticals company media
Company Snapshot

Is Paradigm Biopharmaceuticals a public or private company?

key
Ownership
Public

How many people does Paradigm Biopharmaceuticals employ?

people
Employees
29

What sector is Paradigm Biopharmaceuticals in?

pie chart
Sector
Health Care

Where is the head office for Paradigm Biopharmaceuticals?

location pin
Head Office
Victoria, Australia

What year was Paradigm Biopharmaceuticals founded?

founded flag
Year Founded
2014
What does Paradigm Biopharmaceuticals specialise in?
/Biotech /Pharmaceutical /Health /Medtech /Technology /Drug /Medical

What are the products and/or services of Paradigm Biopharmaceuticals?

Overview of Paradigm Biopharmaceuticals offerings
Osteoarthritis: Paradigm Biopharmaceuticals is developing ZilosulĀ® (iPPS) for the treatment of osteoarthritis, with Phase 3 trials underway.
Respiratory: Paradigm Biopharmaceuticals is developing Pentosan Polysulfate Sodium to target ARDS based on its multiple mechanisms of action outlined in preclinical studies.
Lysosomal Storage Diseases: Paradigm Biopharmaceuticals is developing Pentosan Polysulfate Sodium to help manage bone and joint manifestations, chronic pain, and physical disability, key clinical manifestations of MPS I which remain despite treatment with HSCT and ERT.

Who is in the executive team of Paradigm Biopharmaceuticals?

Paradigm Biopharmaceuticals leadership team
  • Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC
    Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC
    Founder, MD & Executive Chairman
  • Dr. Donna L. Skerrett M.D., MS
    Dr. Donna L. Skerrett M.D., MS
    Chief Medical Officer and Executive Director
  • Ms. Abby  Macnish Niven B.Com., B.Sc., C.F.A.
    Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A.
    Interim Company Secretary & Interim CFO
  • Dr. Ravi  Krishnan
    Dr. Ravi Krishnan
    Chief Scientific Officer
  • Mr. Simon  White
    Mr. Simon White
    Director of Investor Relations
  • Dr. Michael  Imperiale
    Dr. Michael Imperiale
    Global Head of Drug Safety & MPS
  • Ms. Beverley  Huttmann
    Ms. Beverley Huttmann
    Commercial Head
  • Ms. Michelle  Coffey
    Ms. Michelle Coffey
    Global Head of Regulatory Affairs